- Home
- SDHC vs WGS Comparison
SDHC vs WGS Comparison
Compare SDHC & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHC
- WGS
- Stock Information
- Founded
- SDHC 2008
- WGS 2017
- Country
- SDHC United States
- WGS United States
- Employees
- SDHC N/A
- WGS N/A
- Industry
- SDHC
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- SDHC
- WGS Technology
- Exchange
- SDHC Nasdaq
- WGS Nasdaq
- Market Cap
- SDHC 1.5B
- WGS 1.5B
- IPO Year
- SDHC 2024
- WGS N/A
- Fundamental
- Price
- SDHC $30.48
- WGS $68.43
- Analyst Decision
- SDHC Hold
- WGS Strong Buy
- Analyst Count
- SDHC 6
- WGS 5
- Target Price
- SDHC $32.10
- WGS $67.00
- AVG Volume (30 Days)
- SDHC 50.6K
- WGS 753.8K
- Earning Date
- SDHC 11-12-2024
- WGS 10-29-2024
- Dividend Yield
- SDHC N/A
- WGS N/A
- EPS Growth
- SDHC N/A
- WGS N/A
- EPS
- SDHC 4.71
- WGS N/A
- Revenue
- SDHC $905,304,000.00
- WGS $267,228,000.00
- Revenue This Year
- SDHC $24.64
- WGS $43.70
- Revenue Next Year
- SDHC $23.29
- WGS $16.78
- P/E Ratio
- SDHC $6.48
- WGS N/A
- Revenue Growth
- SDHC 17.46
- WGS 29.41
- 52 Week Low
- SDHC $20.55
- WGS $1.29
- 52 Week High
- SDHC $39.50
- WGS $89.11
- Technical
- Relative Strength Index (RSI)
- SDHC 34.89
- WGS 51.05
- Support Level
- SDHC $30.01
- WGS $71.45
- Resistance Level
- SDHC $37.90
- WGS $82.18
- Average True Range (ATR)
- SDHC 1.93
- WGS 7.58
- MACD
- SDHC -0.37
- WGS -1.36
- Stochastic Oscillator
- SDHC 5.89
- WGS 17.21
About SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. The company has organized into five geographical segments so their reportable segments include Atlanta, Raleigh, Charlotte, Nashville, and Alabama which consists of both Birmingham and Huntsville.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.